Long-Term Outcomes After Cabazitaxel vs Paclitaxel as a Neoadjuvant Treatment in Patients With Triple-Negative or Luminal B/HER2-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
ESMO Open 2024 Apr 24;9(5)103009, P Meyer-Wilmes, J Huober, M Untch, JU Blohmer, W Janni, C Denkert, P Klare, T Link, K Rhiem, C Bayer, M Reinisch, V Bjelic-Radisic, DM Zahm, C Hanusch, C Solbach, G Heinrich, AD Hartkopf, A Schneeweiss, P Fasching, N Filmann, V Nekljudova, J Holtschmidt, E Stickeler, S LoiblFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.